The podocyte as a direct target of immunosuppressive agents
about
Ethnic Differences in Childhood Nephrotic SyndromeGenome-wide screening for genes associated with FK506 sensitivity in fission yeastNon-immunologic actions of calcineurin inhibitors in proteinuric kidney diseases.Twisted gastrulation, a BMP antagonist, exacerbates podocyte injurySteroid-sensitive nephrotic syndrome in children: triggers of relapse and evolving hypotheses on pathogenesis.Influence of tacrolimus on podocyte injury inducted by angiotensin II.Insight into response to mTOR inhibition when PKD1 and TSC2 are mutatedTacrolimus Protects Podocytes from Injury in Lupus Nephritis Partly by Stabilizing the Cytoskeleton and Inhibiting Podocyte Apoptosis.Activation of the IL-2 Receptor in Podocytes: A Potential Mechanism for Podocyte Injury in Idiopathic Nephrotic Syndrome?The podocyte as a direct target for treatment of glomerular disease?Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent modelsDivergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injuryPhysiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.The struggle for energy in podocytes leads to nephrotic syndrome.Childhood nephrotic syndrome--current and future therapies.An evaluation of sirolimus in renal transplantation.A drug safety evaluation of everolimus in kidney transplantation.Small molecule membrane transporters in the mammalian podocyte: a pathogenic and therapeutic target.Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.Primary focal segmental glomerulosclerosis: miRNAs and targeted therapies.Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.Immunology of idiopathic nephrotic syndrome.Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.The critical role of Krüppel-like factors in kidney disease.The role of novel biomarkers in childhood idiopathic nephrotic syndrome: a narrative review of published evidence.Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury.Efficacy of tacrolimus in the treatment of children with focal segmental glomerulosclerosis.Krüppel-Like Factor 15 Mediates Glucocorticoid-Induced Restoration of Podocyte Differentiation Markers.Analysis of T Cell Subsets in Adult Primary/Idiopathic Minimal Change Disease: A Pilot Study.Chrysin ameliorates podocyte injury and slit diaphragm protein loss via inhibition of the PERK-eIF2α-ATF-CHOP pathway in diabetic mice.Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial.mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome.Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database.Hypertension in malignancy-an underappreciated problem.Polymer Nanoparticle Engineering for Podocyte Repair: From in Vitro Models to New Nanotherapeutics in Kidney Diseases.Do Foxp3+ Regulatory T Cells (Treg Cells) Play a Role in the Immunopathogenesis of Primary/Idiopathic Minimal Change Disease?
P2860
Q26752347-56DC32CF-0464-47E3-A443-7C96C5418F8AQ33995703-2538AB84-B861-4F7A-B280-5C24F3BFB031Q34496366-AEEFFB2B-6E0C-4599-A19B-645DF7769334Q35106728-F88F1AF9-EDB4-4D5D-9D5D-B90FB0322526Q35233125-4BAC4CCF-1334-4F4F-A31E-D4962D99A407Q35554968-FF56315E-2891-4C5F-8568-9DA728AB42B2Q35664471-F72CEF86-63CC-43B3-A0AE-C80ECFF65EC1Q35687688-A881FD01-7E02-483B-8C56-30012B561BBAQ36070424-34DFE228-D81F-4592-B34E-3D9DEA6DCD38Q37139449-57E7D031-205B-49B1-8E7D-285CB3E73454Q37223452-D0B319D2-BD61-4196-BC1E-B5915175A751Q37274491-54EB1EBD-07D8-4E9E-8703-A9A18DC3E2D7Q37895173-A0A2CCC6-AEC4-4E08-9C2A-A47BCA42C697Q37904098-D0C77A7E-8E61-47BB-BC01-2BDC7E3A818CQ37995467-FCDC1807-A444-445E-A14A-699C3169DCE5Q38017937-A8C70355-A187-4D61-A782-CDCA0C34C267Q38038696-356DFFC6-749C-480D-AA4B-4E1129629B15Q38041260-BA6651AF-39AD-4D25-977E-7792CB535DAFQ38269878-94130394-42F8-4D33-B10C-AAE3086C9352Q38395906-D906B11D-9323-4679-93C8-84B45A4F59C5Q38804869-2BA2EAAB-0606-4288-9D98-7832E641AA3AQ38805701-F0A86979-E012-4C88-9385-ACA85E270759Q38815449-60808DC1-CAB5-4374-BA1F-9322F0C64BFEQ38829694-B8929022-CF7D-4FBE-801F-2F2B1B1A3F85Q39010381-427B21D5-5923-4E46-A95F-D94A0A957A2FQ39374379-58037B67-9241-48F0-919D-7256BA1A2383Q41548278-04FC94E7-E088-4622-95E0-9A09C4641EB4Q46959706-AF31DEEB-3364-4A35-861F-2EFAB49D2EACQ48052536-2C3D2A9F-532A-4961-9C55-27464A7E9631Q48054270-46C2042A-3B8F-4E75-8C9D-985317D2A295Q51002474-77F4E455-7F4D-41D7-96CA-56D072CDEF47Q51067478-4049C4BC-1A4A-493C-9819-9675AF56300CQ51536098-EA8C6100-3531-4BC0-A56E-92EC8F09286EQ54351691-9591CD11-6898-46CD-8F90-8025042EF6F1Q54392480-EE5AC22E-5B13-4B04-8C00-9FAEF1AF91E1Q55071881-E0E6A16B-BCE7-4358-B315-C656AFF8C79CQ55715653-078F3A31-0C9A-40ED-BF06-47F99694C956Q59048750-79E1396F-1C64-4B23-BFE2-7345809CF97F
P2860
The podocyte as a direct target of immunosuppressive agents
description
im Oktober 2010 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2010
@uk
name
The podocyte as a direct target of immunosuppressive agents
@en
The podocyte as a direct target of immunosuppressive agents
@nl
type
label
The podocyte as a direct target of immunosuppressive agents
@en
The podocyte as a direct target of immunosuppressive agents
@nl
prefLabel
The podocyte as a direct target of immunosuppressive agents
@en
The podocyte as a direct target of immunosuppressive agents
@nl
P2093
P2860
P356
P1476
The podocyte as a direct target of immunosuppressive agents
@en
P2093
E. Schonenberger
J. H. Ehrich
P2860
P356
10.1093/NDT/GFQ617
P407
P577
2010-10-11T00:00:00Z